Novocure Ltd (NASDAQ:NVCR) shares climbed about 4.3% in premarket trading Wednesday after the company said U.S. regulators restored its Medicare billing authorization, removing uncertainty around reimbursement for its cancer therapy services.
The company announced that its U.S. subsidiary, Novocure Inc., received confirmation from the Centers for Medicare & Medicaid Services (CMS) that a previous revocation of billing privileges had been withdrawn. CMS reinstated the company’s Medicare billing status retroactively to December 17, 2025.
Billing privileges had initially been revoked on January 29, 2026, also effective December 17, 2025. Novocure said the action stemmed from an administrative issue tied to its routine triannual re-validation process rather than any failure to meet qualification requirements.
Throughout the suspension period, the company continued treating existing patients and onboarding new ones. Novocure added that it does not expect any impact on revenue recognition related to services delivered while billing privileges were temporarily revoked.
The reinstatement removes a key overhang for investors, as it restores clarity around Medicare reimbursement for the company’s tumor treating fields therapy, a treatment used in oncology care.